FDA Approves Tisagenlecleucel for B-cell ALL, Tocilizumab for Cytokine Release Syndrome

On August 30, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to tisagenlecleucel (Kymriah^®, Novartis Pharmaceuticals Corp.) for the treatment of patients up to age 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.